The report discusses the reauthorization of Iclusig by the FDA with a new label and REMS, leading to an upgrade of Ariad Pharmaceuticals' stock to 'Outperform' and an increased price target of $12. The report highlights the limited downside risk due to REMS and PMRs, positive physician feedback, potential for safer administration, and other potential indications for Iclusig. The report also provides financial data and stock performance metrics for Ariad Pharmaceuticals.
doj/DataSet10/EFTA01450727.pdf
{"title":"ARIAD Pharmaceuticals, Inc. - Iclusig Comes Back With a New Label and REMS; Upgrade to Outperform and Increase Price Target to $12","key_people":["Y. Katherine Xu, Ph.D.","Filippo Petti"],"document_date":"2013-12-23","document_type":"tabular","key_locations":["Cambridge, Massachusetts"],"document_subtype":"Equity Research Report","key_organizations":["William Blair","ARIAD Pharmaceuticals, Inc.","FDA"]}